Conditional sentence

Global Medical Device Connectivity Market Analysis Report 2023-2024 and 2029: Rising Demand for Seamless Communication and Increased Efficiencies Fueling Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Managed Care, Mobile, Wireless, Internet, Telemedicine, Virtual Medicine, IOT (Internet of Things), Medical Devices, Technology, Hospitals, 5G, Biotechnology, Practice Management, Health, Hospital, Vital signs, Monitoring, Organization, Pump, Growth, Prevalence, Communication, Digital, Application, Intelligence, Internet of things, COVID-19, Education, Conditional sentence, Research, Health information management, Human services, Health information exchange, Electronic health record, Ecosystem, EHR, HIE, Movement, Medical device

The global medical device connectivity market in 2023 stood at US$2.35 billion, and is likely to reach US$8.84 billion by 2029.

Key Points: 
  • The global medical device connectivity market in 2023 stood at US$2.35 billion, and is likely to reach US$8.84 billion by 2029.
  • The global medical device connectivity market value is projected to grow at a CAGR of 24.71%, during the forecast period of 2024-2029.
  • North America medical device connectivity market enjoyed the highest market share in 2023, primarily owing to reasons such as the high prevalence of chronic diseases and increasing adoption of EHRs.
  • By Technology: According to the report, the global medical device connectivity market is bifurcated into three technologies: Wireless, Wired and Hybrid.

Global Digital Biomarkers Market Outlook & Forecast 2024-2029: Rise in Digitized Virtual Clinical Research, Increasing Focus on Drug Development and Expanding Applications in Mental Health - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 21, 2024
Mobile, Wireless, Other Technology, Telecommunications, Other Science, Data Analytics, Pharmaceutical, Research, Hardware, Mental Health, Medical Devices, Data Management, Consumer Electronics, Wearables, Mobile Technology, Technology, Women, Science, Biotechnology, Seniors, Biometrics, Medical Supplies, Men, Health, Artificial Intelligence, Health Technology, Professional Services, Health Insurance, Consumer, Cardiology, Culture, Conditional sentence, Growth, Prevalence, Neurology, Digital, Vital signs, COVID-19, Patient, Heart rate, Tablet, Biomarker, Health care, Software, Diagnosis, Drug development, USD, Ageing, Medical imaging

Factors such as an aging population, increasing healthcare costs, and a shift towards value-based care have driven the adoption of digital biomarkers.

Key Points: 
  • Factors such as an aging population, increasing healthcare costs, and a shift towards value-based care have driven the adoption of digital biomarkers.
  • The rise in digitized virtual clinical research is a significant trend in the global digital biomarkers market, driven by advances in remote monitoring technologies and the need for more efficient, patient-centric clinical trials.
  • The global digital biomarkers market is witnessing a notable trend with an increasing focus on drug development.
  • A prominent trend in the global digital biomarkers market is the increasing number of vendor collaborations and partnerships.

Ontrak Health Announces the Launch of the Ontrak Advanced Engagement System, Ushering in the Next Era of AI-enabled Behavioral Healthcare

Retrieved on: 
Thursday, March 21, 2024
Software, Managed Care, General Health, Professional Services, Telemedicine, Virtual Medicine, Data Management, Technology, Artificial Intelligence, Health Technology, Data Analytics, Practice Management, Health, Diagnosis, Depression, ROI, Conditional sentence, EDI, Algorithm, Face, Risk, Research, Anxiety, Prescription, AI, Safe harbor, OTRK, Life, HITECH, Data exchange, Workforce, Evidence-based practice, Data management, Medical device

Ontrak Health (NASDAQ: OTRK), a leading AI-powered and tech-enabled behavioral healthcare company, today announced the launch of its Ontrak Advanced Engagement System.

Key Points: 
  • Ontrak Health (NASDAQ: OTRK), a leading AI-powered and tech-enabled behavioral healthcare company, today announced the launch of its Ontrak Advanced Engagement System.
  • Built on a foundation of real-world AI application, the Ontrak Advanced Engagement System enables member engagement at greater scale and with greater efficiency than ever before.
  • Several other components of the Ontrak Advanced Engagement System continue to improve Ontrak’s industry-leading Care Coaching.
  • To ensure that Ontrak Care Coaches align with best practices, the Ontrak Advanced Engagement System also includes AI-driven quality assessment and fidelity assessment tools.

Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, DTRA, Conditional sentence, Inflammation, Viral, Marburg virus disease, Human, TLR7, Therapy, Lassa mammarenavirus, Lassa fever, Bleeding, Toll-like receptor 7, Vaccine

Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.

Key Points: 
  • Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.
  • The objective of the program is to evaluate the efficacy of PRTX007 in a series of animal models for Lassa fever and establish an effective treatment method of Lassa virus in humans.
  • “Primmune has demonstrated broad spectrum antiviral activity with PRTX007 and with related compounds from our discovery and development program,” said Charlie McDermott, President, Chief Executive Officer and Director of Primmune Therapeutics.
  • “PRTX007’s novel immunologic approach has the potential for combination use with direct acting anti-viral agents – enabling widely applicable utility in the treatment of Lassa fever and other hemorrhagic viruses.”

New Report Shows How Dental Disparities Impact Veterans’ Productivity and Well-Being

Retrieved on: 
Tuesday, March 19, 2024
Public Policy, Government, Healthcare Reform, General Health, Health, Minter, Socialization, Dental care, Dentistry, Dentures, Conditional sentence, National Health, Social anxiety, Tooth decay, Policy, MD, NHANES, MBA, American Institute, Mouth, Workforce, Federally Qualified Health Center, MEPS, CPH, Workplace, Dental public health, Doctor of Health Science, Health insurance

The report finds that lack of access to dental care leads to significant losses in productivity time and money for veterans and their employers.

Key Points: 
  • The report finds that lack of access to dental care leads to significant losses in productivity time and money for veterans and their employers.
  • “When veterans are in dental pain or experience social anxiety from unmet dental needs, their workplaces can suffer from low productivity.
  • Veterans with urgent dental needs were approximately five times more likely to report poor functioning and work compared to veterans who needed routine dental care.
  • The report underscores the urgent need for more integrated health care solutions that prioritize cost-effective dental care for our nation’s veterans.

Global Prefilled Syringes Market Trends and Forecasts, 2024-2035: Innovations in Prefilled Syringes Address Patient Compliance and Safety Concerns - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 19, 2024
Pharmaceutical, Health, Medical Supplies, Molecule, Growth, Prevalence, Rheumatoid arthritis, Diabetes, Anaphylaxis, Risk, Patient, Conditional sentence, Purpose, Research, Usability, BD (company), Injury, Glass, Syringe, CDC, Injection, Safety, Privacy, USD, State, Pharmaceutical industry

The global prefilled syringes market size is estimated to grow from USD 3.02 billion in 2024 to USD 4.97 billion by 2035, representing a CAGR of 4.6% during the forecast period 2024-2035.

Key Points: 
  • The global prefilled syringes market size is estimated to grow from USD 3.02 billion in 2024 to USD 4.97 billion by 2035, representing a CAGR of 4.6% during the forecast period 2024-2035.
  • One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the prefilled syringes market, over the forecast period.
  • The pre-filled syringes market features around 125 prefilled syringes.
  • The current pre-filled syringes market landscape features the presence of 35 players that have the required expertise to develop and manufacture prefilled syringes.

Tilak Healthcare Strengthens Its Leadership Team

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Human Resources, Optical, Finance, Health, Health Technology, Professional Services, Other Health, Retina, Social Security, Conditional sentence, HEC Paris, Euronext Growth, CFO, Partnership, Knowledge, Health care, Information, University, Prescription, Head, Visual impairment, Laboratory, ParisTech, Drug, Alcon, Social, Genomics, Pharmacy, Directorate, Multimedia, Ministry, Doctorate

Tilak Healthcare, a leading company in digital health for the monitoring of chronic eye diseases, announces the appointment of three experts to support the leadership team, currently composed of Edouard Gasser (CEO & co-founder), Philip Bouchet (Chief Operating and Product Officer), and Dr. Bénigne Mathieu (Chief Business Officer).

Key Points: 
  • Tilak Healthcare, a leading company in digital health for the monitoring of chronic eye diseases, announces the appointment of three experts to support the leadership team, currently composed of Edouard Gasser (CEO & co-founder), Philip Bouchet (Chief Operating and Product Officer), and Dr. Bénigne Mathieu (Chief Business Officer).
  • For Benoît Gueugnon, CFO: "I would like to thank the management team as well as the investors of Tilak Healthcare (iBionext, Elaia, Swen Capital, Matmut, Caphorn, and Laboratoires Théa).
  • For Dr. Patricia Zilliox: "I am impressed by Tilak Healthcare's journey, establishing itself as a leader in digital health in ophthalmology.
  • Undoubtedly, these achievements and the quality of the team are undeniable assets for approaching the American market."

GlobalData Report Highlights Staggering Economic Costs for Pennsylvania of $19.9 Billion Due to Obesity

Retrieved on: 
Tuesday, March 19, 2024
Public Policy, Government, Healthcare Reform, General Health, Health, Death, Overweight, Culture, Comment, Disease, Federation, Education, Conditional sentence, Head, Weight loss, GlobalData, News, Insurance, Woman, Parity, Medicaid, Workforce, DSM-IV codes, Eli Lilly and Company, Welfare, Medicare, Pharmaceutical industry

GlobalData’s report, ‘ Obesity’s Impact on Pennsylvania's Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of Pennsylvania, as well as the impact on state tax revenue collections and costs.

Key Points: 
  • GlobalData’s report, ‘ Obesity’s Impact on Pennsylvania's Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of Pennsylvania, as well as the impact on state tax revenue collections and costs.
  • In Pennsylvania, approximately one-third of adults are classified as having obesity (33.4%), and another third have overweight (34.3%) in 2022.
  • Employers in Pennsylvania paid an extra $2.3 billion in higher medical expenditures for health complications attributed to obesity and overweight.
  • The Obesity Action Coalition’s Stop Obesity Weight Bias Campaign includes media guidelines and bias-free image gallery .

US Biosimilar Industry Projected to Surge With CAGR of 40% Through 2028: New Study Highlights Market Growth and Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Pharmaceutical, Health, Competitive advantage, Conditional sentence, Incidence, Patient, Research, Cancer, Oncology, Ecosystem, Compound annual growth rate, FDA, Movement, Medicine, Ageing, Hook effect, Generic drug

The study delves into the complex ecosystem of the US Biosimilar market, identifying the critical factors that contribute to its projected Compound Annual Growth Rate (CAGR) of approximately 40% over the next five years.

Key Points: 
  • The study delves into the complex ecosystem of the US Biosimilar market, identifying the critical factors that contribute to its projected Compound Annual Growth Rate (CAGR) of approximately 40% over the next five years.
  • Key Insights from the Report:
    The cost-effectiveness of Biosimilar drugs is key to market growth as patients seek affordable alternatives to high-priced generic drugs.
  • The Competitive Edge in Biosimilars:
    The US Biosimilar market is characterized by a robust presence of both domestic and global pharmaceutical titans.
  • The research highlights the strategies employed by these entities to navigate the market dynamics and enhance their foothold within the industry.

USA Patient Registry Software Market Outlook to 2028, Featuring IQVIA, Optum (UnitedHealth Group), Phytel, Dacima Software, FIGmd, Syapse and Pharos Innovations - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Research, Software, University, Infectious Diseases, Education, Hospitals, Health Technology, Genetics, Health Insurance, Data Management, Science, Technology, Clinical Trials, Biotechnology, FDA, Insurance, Health, Professional Services, IOT (Internet of Things), Data Analytics, White House, Federal Government, Practice Management, Managed Care, Other Health, Public Policy, Government, Pharmaceutical, Other Science, Pancreatic disease, Consolidated, Patient, Conditional sentence, Optum, Health information management, Food and Drug Administration, Geography, NPF, RWE, Internet of things, Openclinica, DNA, Policy, Electronic health record, NIH, City, Privacy, CMS, Food, Organization, Prevalence, Federation, Internet, Cancer, Drug development, IQVIA, Evidence-based medicine, RDCRN, Type, Data science, Caregiver, Public health surveillance, Government agency, Registry, EHR, CDC, National Institutes of Health, Bangladesh Technical Education Board, Medicare, Collection, Medical device

The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.

Key Points: 
  • The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.
  • Patient registry software could facilitate data sharing and analysis among these entities, leading to increased adoption
    The patient registry software market in the USA is a part of the broader healthcare information technology sector.
  • Key players in the USA patient registry software market includes IQVIA, Dacima Software, OpenClinica, FIGmd, Dendrite Clinical Systems and various universities conducting medical clinical studies.
  • As technology & data science continue to evolve, the patient registry software market is likely to incorporate more advanced analytics techniques.